New hope for rare, aggressive kidney cancer after other treatments fail
NCT ID NCT07438626
Summary
This study is testing whether a new drug called sacituzumab tirumotecan can help control an advanced and aggressive form of kidney cancer called SMARCB1-deficient renal medullary carcinoma. It is for adult patients whose cancer has continued to grow despite receiving at least one prior treatment. The main goals are to see if the drug shrinks tumors and controls the disease, while closely monitoring for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHASE II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.